Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: A prospective randomised study

M. Colozza, G. Bisagni, A. M. Mosconi, S. Gori, C. Boni, R. Sabbatini, A. Frassoldati, R. Passalacqua, A. Rosa Bian, C. Rodinò, E. Rondini, R. Algeri, S. Di Sarra, V. De Angelis, G. Cocconi, M. Tonato

Research output: Contribution to journalArticle

Abstract

We compared a relatively short regimen of monochemotherapy with epirubicin versus polychemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as adjuvant treatment for stage I and II breast cancer patients. 348 patients with oestrogen receptor negative (ER-) node negative and ER- or ER+ node-positive with

Original languageEnglish
Pages (from-to)2279-2288
Number of pages10
JournalEuropean Journal of Cancer
Volume38
Issue number17
DOIs
Publication statusPublished - Nov 2002

    Fingerprint

Keywords

  • Adjuvant therapy
  • Breast cancer
  • CMF
  • Epirubicin
  • Randomised study

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Colozza, M., Bisagni, G., Mosconi, A. M., Gori, S., Boni, C., Sabbatini, R., Frassoldati, A., Passalacqua, R., Bian, A. R., Rodinò, C., Rondini, E., Algeri, R., Di Sarra, S., De Angelis, V., Cocconi, G., & Tonato, M. (2002). Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: A prospective randomised study. European Journal of Cancer, 38(17), 2279-2288. https://doi.org/10.1016/S0959-8049(02)00452-5